MedTrace Logo

Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis

NCT04144101 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-10-30

No results posted yet for this study

Summary

Comparison of lower dosage etoricoxib (60 mg daily) with aceclofenac (100 mg bid) for their efficacy and safety in the treatment of rheumatoid arthritis (RA).

Conditions

Interventions

DRUG

Etoricoxib

Etoricoxib 60 mg QD Oral

DRUG

Aceclofenac

Aceclofenac 100 mg BID Oral

Sponsors & Collaborators

  • Chung Shan Medical University

    lead OTHER

Principal Investigators

  • Cheng Ching Wei, Ph. D. · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-01
Primary Completion
2007-07-31
Completion
2007-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04144101 on ClinicalTrials.gov